MPOX CASE QUESTIONNAIRE

| SUMMARY | | | | |
|--|---|--|--|--|
| Date of notification: | NCIMS ID: | | | |
| Date of interview:// | Interviewer: | | | |
| Person interviewed if not case: | NCIMS updated: | | | |
| High risk group refer to Mpox Control Guidelines, examp | oles: health care worker, hostels 🔲 Yes 🔲 No | | | |
| Case classification refer to case definition | ☐ Confirmed ☐ Probable ☐ Suspected | | | |
| Where was the case's most likely source of infection? | | | | |
| \square Locally acquired in NSW \square Acquired interstate (s | pecify state/territory): | | | |
| ☐ Unknown ☐ Acquired overseas (sp | ecify country): | | | |
| Is there an epidemiological link? | Outbreak ID if applicable: | | | |
| \square No epidemiological link \square Contact of a known ca | ii avaitable, provide contact(s) | | | |
| ☐ Contact of a suspecte | ed case NCIMS no: | | | |
| Case status: ☐ Alive ☐ Died due to mpox | ☐ Died due to other / unknown cause ☐ Unknown | | | |
| Cause of death if known: | Date of death:// | | | |
| SECTION 1: Initial demographics | | | | |
| First name: | | | | |
| Last name: | | | | |
| Date of birth:/ Age (year | rs): | | | |
| Sex at birth: ☐ Male ☐ Female ☐ Anothe | er term (specify): | | | |
| Current gender: ☐ Male ☐ Female ☐ Non-bi | nary 🗆 Another term (specify): | | | |
| Street address: | | | | |
| Suburb: | Postcode: | | | |
| Temporary address if applicable: | | | | |
| Contact number: | | | | |
| Main language other than English spoken at home? | | | | |
| Is an interpreter required? ☐ No ☐ Yes, s | pecify language: | | | |
| Treating clinician's details | | | | |
| Name of treating clinician: Name of clinic: | | | | |
| Clinic address: Clinic phone number: | | | | |
| SECTION 2: Illness | | | | |
| Section 2a: Prodromal symptoms | | | | |
| Arthalgia (sore joints) 🔲 Yes | □ No □ Unknown Onset:// | | | |
| Back pain ☐ Yes | □ No □ Unknown Onset:// | | | |
| Fever (incl chills) 🔲 Yes | □ No □ Unknown Onset:// | | | |
| Headache □ Yes | □ No □ Unknown Onset:// | | | |
| Lymphadenopathy (swollen lymph nodes) 🔲 Yes | □ No □ Unknown Onset:// | | | |
| Myalgia (muscle aches) 🔲 Yes | □ No □ Unknown Onset:// | | | |

☐ Yes

Onset: ____/ ___/ __

| Section 2b: Rash symptoms | Rash stage: | Rash location: | Onset date: |
|---|---|--------------------------------|--|
| Describe rash stage, location, and appearance: | ☐ Macules ☐ Vesicles ☐ Papules ☐ Scabs ☐ Healed ☐ No rash | | // |
| Section 2c: Other symptoms a | nd notes i.e., signif | cant sequelae like keratitis | |
| | | | |
| Clinical history | | | |
| Is the case immunocompromi | sed? | Yes | □ No □ Unknown |
| Is the case pregnant? | | Yes, how many weeks: | □ No □ Unknown |
| Post-birth i.e., mpox detected at or after | delivery | Post-birth | |
| Was case hospitalised due to | mpox? | Yes, specify date: / / _ | MRN: |
| | | Discharge date:// | _ 🗆 No 🗀 Unknown |
| Was the case admitted to ICU | due to mpox? 🛚 | Yes, specify date:// | □ No □ Unknown |
| SECTION 3: Vaccination | | | |
| Previously received mpox/sm | allpox vaccine? 「 | Yes, specify below | □ No □ Unknown |
| Dose 1 brand: | | | |
| Dose i biana. | Date7 | / | ed Divriactice record D Ain |
| Dose 2 brand: | Date:/ | / | ed □ Dr/Practice record □ AIR |
| SECTION 4: Risk factors | | | |
| Exposure period | S | ymptom onset | Infectious period |
| (-21 days) | | (0 days) | (until lesions crust over) |
| Start date:// | Date | :/ | End date: / / |
| Section 4a: Travel | | | |
| Is the case a visitor or travelle | | te traveller | No, NSW resident |
| ☐ International traveller | | | No, Now resident |
| Did the case spend any of thei ☐ Overseas, list countries: | i exposure periou (| outside of NSW: | |
| | | □ Unknown □ | No [move to Section 4b] |
| ☐ Interstate, list states/territo | | | No [move to Section 45] |
| If travelled, departure from N | | | |
| Section 4b: Travel contact | ISW date:/_ | / | |
| | contact or high-rick | contact with recent overseas o | r interstate travel? i.e. regular partner |
| ☐ Yes ☐ Unknown | _ | o [move to Section 4c] | i interstate travet: i.e. regular partirer |
| If yes, was the travel: | | | |
| ☐ Overseas travel, specify cit | y, country: | | |
| ☐ Interstate travel specify, cit | y, state/territory: | | |
| Travel contact's departure date if known: | | Travel cont if known: | act's return date// |
| Did the travel contact have any | symptoms similar to | the case? | |
| ☐ Yes, approx. onset date: | | □ No □ Unknown | |

| Section 4c: Sexual exposure | | | | |
|---|-----------------------------------|------------------------------|------------------------------------|--|
| Did the case report any of the following sexual exposures* during the exposure period? Based on case's sex at birth | | | | |
| ☐ Male only ☐ | | | | |
| ☐ Unknown ☐ | No sexual exposure [mov | ve to Section 4d] | | |
| Type of sexual encounter | ? Select all that apply | | | |
| ☐ Casual partner ☐ | Regular partner 🔲 S | ex worker | ex worker | |
| Where was the sexual co | ntact? Select all that app | ply | | |
| □ NSW | | ☐ Interstate, specify: | | |
| ☐ Overseas, specify: | | | | |
| Did the case attend any h | igh-risk sexual settings? | ? | | |
| ☐ SOPV(s), specify: | | ☐ Brothel(s), specify: | | |
| ☐ Other, specify: | | | | |
| Notes on sexual exposure | e(s) i.e., condomless sex, | multiple partners, group se | X | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Section 4d: Other high-ris | k encounters (non-sexu | al) | | |
| _ | | - | sio, prolonged skin touching | |
| ☐ Yes, specify: | | □ No | □ Unknown | |
| Refer to APPENDIX for co | ntact tracing line list | | | |
| | | | | |
| SECTION 5: Additional de | mographics | | | |
| Email: | | | | |
| Does the case identify as | being of Aboriginal and/ | or Torres Strait Islander or | igin? | |
| ☐ Aboriginal | ☐ Torres Strait Islander | r 🔲 Both Aboi | riginal and Torres Strait Islander | |
| ☐ Non-Indigenous | □ Unknown | ☐ Not state | | |
| Country of birth: | | | · | |
| | | | | |
| Ethnicity refer to ABS: | | | | |
| Occupation: | | | | |
| SECTION 6: Laboratory in | vestigations | | | |
| Test: PCR (MPXV) | | Not detected ☐ Per | nding 🗆 Not done | |
| | Dottoeted — | | | |
| Collection date(s) | Specimen site(s) | Laboratory | Specimen ID(s) | |
| | | | | |
| | | | | |
| | | | | |
| If required, specimen ref | erred to for typing 🛚 | Yes, specify date: / | _/ □ No | |
| | | | | |
| SECTION 7: Attempts to c | ontact case | | | |
| Date | Time | Comments | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| Section 8: Notes | | | | |
|------------------|--|--|--|--|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| APPENDIX: Contact tracing | | | | | | | | | | |
|---|--------------|--|---|---|-----------------------|--------------------------|------------|---|--------------------|-------|
| Contact type: | Contact name | Contact details: | Case consents to | | Date of last | Contact | Symptoms | Risk | Info | Notes |
| i.e. dating app, household, party, SOPV, workplace | | i.e. phone/email/social media name/handle | PHU can contact this contact? Yes/No/Unk | PHU can disclose case identify to contact? Yes/No/Unk | contact dd/mm/yyyy | vaccinated Yes/No/Unk | Yes/No/Unk | assessment High/Med/Low and Up/Downtream | provided Yes/No | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

| MPOX Public Health Unit Checklist | | | | | |
|--|--------|--|--|--|--|
| Contact the patient and/or the patient's doctor | | | | | |
| Case interviewed: Confirm results of relevant pathology tests Confirm onset of symptoms (if any) Obtain case's risk exposure history (including travel, sexual and high-risk exposures) Ask smallpox/mpox vaccination history Identify likely source of infection Identify upstream and downstream contacts Seek permission to speak to identified contacts Confirm where case is recovering, if not usual residence Ensure case has been informed of prevention activities i.e. exclusion for high-risk settings Ensure that the case is aware of diagnosis/provide case factsheet Clearance advice provided to case, if appropriate | Notes: | | | | |
| ☐ Follow up with GP or SHC to ensure case is in care: | Notes: | | | | |
| Contact the contact(s) | I | | | | |
| Ensure contact tracing has commenced: Interview contacts and inform them of their exposure Check if contacts have any symptoms Confirm contacts vaccination status Advise testing as required Advise PEP vaccination as required Ensure contact monitoring as per Control Guidelines Refer complex contact(s) to SHIL if appropriate Contact(s) provided with contact factsheet | Notes: | | | | |
| Contact the laboratory | | | | | |
| ☐ If required request further testing | Notes: | | | | |
| Confirm case | | | | | |
| ☐ Assess case information against case definition | Notes: | | | | |
| ☐ Update NCIMS, including attaching case interview | Notes: | | | | |
| Communications | | | | | |
| □ Send CD On Call case notification: □ Highlight any cross jurisdictional issues (e.g., interstate or overseas exposures or normal place of residence) □ Alert CD On Call early to any concern – this can include cases outside of MSM community, large contact tracing, clustered cases, and identification of unusual clades □ If required inform infection control team □ If required establish communications pathway with treating team □ If high-risk settings identified inform venue of perceived risk e.g., SOPV, liaise with ACON via CD on Call | Notes: | | | | |